Lexicon Pharmaceuticals (LXRX) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lexicon Pharmaceuticals is the larger company by market cap ($783.1 million vs $756.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXRX | OBX |
|---|---|---|
| Share price | $1.76 | $12.24 |
| Market cap | $783.12M | $756.10M |
| 1-day change | 0.00% | -7.27% |
| YTD return | +53.04% | — |
| 1-year return | +15.79% | — |
| 5-year return | -71.43% | — |
| EPS (TTM) | $-0.16 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $49.97 |
| 52-week low | $1.10 | $12.09 |
| Distance from 52-week high | -34.33% | -75.51% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +158.52% | +218.63% |
| Average volume | 2.87M | 364.47K |
| Shares outstanding | 444.96M | 61.77M |
| Employees | 81 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
LXRX vs OBX FAQ
Which is bigger, Lexicon Pharmaceuticals or Obsidian Therapeutics?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $783.12M compared with $756.10M for Obsidian Therapeutics (OBX).
Are Lexicon Pharmaceuticals and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.